Clonal hematopoiesis, inflammasomes and atherosclerosis
克隆造血、炎症小体和动脉粥样硬化
基本信息
- 批准号:10339390
- 负责人:
- 金额:$ 54.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-15 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:AgeAnti-Inflammatory AgentsAntibodiesAntibody TherapyAntioxidantsApoptoticArterial Fatty StreakAtherosclerosisAutomobile DrivingBindingBlood Cell CountBone Marrow CellsCASP1 geneCardiovascular DiseasesCell DeathCellsCoronary heart diseaseDNADNA FragmentationDefectElderlyEnzymesGenerationsGeneticGenotypeGlycolysisGoalsHematopoiesisHematopoieticHematopoietic stem cellsHumanHuman GeneticsImpairmentInfectionInflammasomeInflammationInterleukin-1Interleukin-1 betaInterleukin-18JAK2 geneLeadLesionLeukocytosisLinkMediatingMetabolicMitochondriaModelingMusMutationMyocardial InfarctionNecrosisPathway interactionsPatientsPersonsPolycythemiaPopulationResistanceRespirationRiskRisk FactorsRoleSignal TransductionSignaling MoleculeSomatic MutationStrokeThrombosisTransplantationVariantbasecardiovascular disorder riskcardiovascular risk factorcoronary eventdensityexperimental studyextracellulargain of functiongenetic variantin vivoloss of functionmacrophagemouse modelneutrophilnovel strategiesoxidationprematurerisk variantsingle-cell RNA sequencing
项目摘要
Project Summary/Abstract
The recent CANTOS trial showed that administration of an antibody targeting IL-1b reduced coronary events,
supporting the concept of anti-inflammatory therapy as a way to reduce cardiovascular disease (CVD). However,
due to a modest effect and an excess of infections this treatment has not been approved for CVD treatment.
This suggests the need for new approaches and for targeting anti-inflammatory therapy to patients who need it
most. Clonal hematopoiesis (CH), a highly prevalent condition in the elderly, arises from somatic mutations that
endow a proliferative advantage to hematopoietic stem cells (HSCs). CH increases the risk of myocardial
infarction and stroke independently of traditional risk factors and in mouse models increases macrophage (Mf)
inflammation and atherosclerosis. This application will seek to elucidate mechanisms linking clonal
hematopoiesis to accelerated atherosclerosis, focusing on one particular cause of CH involving a gain of function
in the signaling molecule JAK2. Relative to other common genetic variants giving rise to CH, this particular
variant JAK2V617F (JAK2VF) increases Jak/Stat signaling, occurs at a younger age and imparts a greater risk of
premature coronary heart disease. Our recent studies have shown a key role of Mf inflammasome activation, IL-
1b secretion and Mf proliferation in promoting atherosclerosis in mice expressing Jak2VF. Il-1b antibody treatment
reduced features of atherosclerotic plaque instability in a mouse model of Jak2VF CH. In human studies we
showed that the myocardial infarction associated with JAK2VF is increased by a common loss of function genetic
variant in LNK that normally acts to suppress JAK/STAT signaling. This proposal will use mouse models that
authentically replicate the human genetic variants to elucidate the mechanisms and consequences of Jak2VF-
mediated inflammasome activation in atherosclerosis and the potential modulation of these effects by Lnk. The
overall hypothesis is that metabolic changes in Jak2VF Mfs lead to Aim2 inflammasome activation, Gasdermin D
cleavage, IL-1 secretion, pryoptotic cell death and necrotic core formation in atherosclerotic lesions. Our studies
may suggest that suggest that precise application of anti-IL-1β or anti-inflammasome therapy based on CH status
and LNK genotype could substantially reduce cardiovascular risk.
项目总结/摘要
最近的CANTOS试验表明,给予靶向IL-1b的抗体可减少冠状动脉事件,
支持抗炎治疗作为减少心血管疾病(CVD)的一种方法的概念。然而,在这方面,
由于效果不佳和感染过多,该治疗尚未被批准用于CVD治疗。
这表明需要新的方法和有针对性的抗炎治疗的患者谁需要它
最多克隆性造血(CH)是老年人中一种非常普遍的疾病,由体细胞突变引起,
赋予造血干细胞(HSC)增殖优势。CH增加心肌梗死的风险
梗死和中风独立于传统的风险因素,在小鼠模型中增加巨噬细胞(Mf)
炎症和动脉粥样硬化。本申请将试图阐明克隆
造血加速动脉粥样硬化,重点是CH的一个特殊原因,涉及功能的获得
信号分子JAK 2中。相对于其他常见的遗传变异引起CH,这种特殊的
JAK 2 V617 F(JAK 2 VF)变异增加了Jak/Stat信号传导,发生在较年轻的年龄,并赋予更大的风险,
早发冠心病我们最近的研究表明,Mf炎性小体激活,IL-10,
1b分泌和Mf增殖促进表达Jak 2 VF的小鼠的动脉粥样硬化。IL-1b抗体治疗
在Jak 2 VF CH小鼠模型中,动脉粥样硬化斑块不稳定性的特征减少。
结果显示,与JAK 2 VF相关的心肌梗死增加了一种常见的遗传功能丧失,
LNK中的一种变体,通常用于抑制JAK/STAT信号传导。该提案将使用小鼠模型,
真实地复制人类遗传变异,以阐明Jak 2 VF的机制和后果,
介导的动脉粥样硬化炎性小体激活和潜在的调制这些影响LNK。的
总体假设是Jak 2 VF Mfs的代谢变化导致Aim 2炎性小体激活,Gasdermin D
动脉粥样硬化病变中的裂解、IL-1分泌、胞浆变性细胞死亡和坏死核心形成。我们的研究
可能提示根据CH状态精确应用抗IL-1β或抗炎体治疗
LNK基因型可显著降低心血管病风险。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALAN richard TALL其他文献
ALAN richard TALL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALAN richard TALL', 18)}}的其他基金
New therapeutic approaches in clonal hematopoiesis and atherosclerosis
克隆造血和动脉粥样硬化的新治疗方法
- 批准号:
10719058 - 财政年份:2023
- 资助金额:
$ 54.41万 - 项目类别:
Clonal hematopoiesis, inflammasomes and atherosclerosis
克隆造血、炎症小体和动脉粥样硬化
- 批准号:
10581564 - 财政年份:2021
- 资助金额:
$ 54.41万 - 项目类别:
Hyperinsulinemia, mTOR activity and plasma lipoproteins
高胰岛素血症、mTOR 活性和血浆脂蛋白
- 批准号:
8275590 - 财政年份:2012
- 资助金额:
$ 54.41万 - 项目类别:
ABCA1/G1 and LXRs in Atherogenesis
ABCA1/G1 和 LXR 在动脉粥样硬化形成中的作用
- 批准号:
10171606 - 财政年份:2011
- 资助金额:
$ 54.41万 - 项目类别:
ABCA1/ABCG1 in myeloid populations and atherogenesis
ABCA1/ABCG1 在骨髓细胞群和动脉粥样硬化形成中的作用
- 批准号:
8675919 - 财政年份:2011
- 资助金额:
$ 54.41万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 54.41万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 54.41万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 54.41万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 54.41万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 54.41万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 54.41万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 54.41万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 54.41万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 54.41万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 54.41万 - 项目类别: